相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。c-Met-targeted chimeric antigen receptor T cells inhibit hepatocellular carcinoma cells in vitro and in vivo
Xiaochen Huang et al.
JOURNAL OF BIOMEDICAL RESEARCH (2022)
hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of 'MET-addicted' cancers
Ilaria Martinelli et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)
c-Met specific CAR-T cells as a targeted therapy for non-small cell lung cancer cell A549
Jingting Min et al.
BIOENGINEERED (2022)
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
Emma C. Morris et al.
NATURE REVIEWS IMMUNOLOGY (2022)
Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors
Xingxing Yuan et al.
INVESTIGATIONAL NEW DRUGS (2021)
CAR T cells in solid tumors: challenges and opportunities
Faroogh Marofi et al.
STEM CELL RESEARCH & THERAPY (2021)
Anti-tumor efficacy of human anti-c-met CAR-T cells against papillary renal cell carcinoma in an orthotopic model
Jun-ich Mori et al.
CANCER SCIENCE (2021)
Bispecific c-Met/PD-L1 CAR-T Cells Have Enhanced Therapeutic Effects on Hepatocellular Carcinoma
Wei Jiang et al.
FRONTIERS IN ONCOLOGY (2021)
Engineering, Characterization, and Biological Evaluation of an Antibody Targeting the HGF Receptor
Claudia Desole et al.
FRONTIERS IN IMMUNOLOGY (2021)
MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies
Matthew Lee et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2021)
c-Met-Specific Chimeric Antigen Receptor T Cells Demonstrate Anti-Tumor Effect in c-Met Positive Gastric Cancer
Chung Hyo Kang et al.
CANCERS (2021)
A Biparatopic Antibody-Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
John O. DaSilva et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer
Cong Chen et al.
ONCOIMMUNOLOGY (2021)
Recent advances and discoveries in the mechanisms and functions of CAR T cells
Rebecca C. Larson et al.
NATURE REVIEWS CANCER (2021)
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
Yi-Long Wu et al.
LANCET RESPIRATORY MEDICINE (2020)
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Paul K. Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
CAR-T design: Elements and their synergistic function
Jayapriya Jayaraman et al.
EBIOMEDICINE (2020)
MET-dependent solid tumours - molecular diagnosis and targeted therapy
Robin Guo et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes
Valeria Leuci et al.
CLINICAL CANCER RESEARCH (2020)
Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer
Juergen Wolf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Oncogene addiction as a foundation of targeted cancer therapy: The paradigm of the MET receptor tyrosine kinase
Eleonora Orlando et al.
CANCER LETTERS (2019)
Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies
Christine M. Parseghian et al.
CLINICAL CANCER RESEARCH (2019)
CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy
Ramona Rotolo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer
Francisco Sanchez-Vega et al.
CANCER DISCOVERY (2019)
Gastric cancer patient with c-MET amplification treated with crizotinib after failed multi-line treatment: A case report and literature review
Guoxin Hou et al.
MATHEMATICAL BIOSCIENCES AND ENGINEERING (2019)
Tumour heterogeneity and resistance to cancer therapies
Ibiayi Dagogo-Jack et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
miR-205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling
Cristina Migliore et al.
EMBO MOLECULAR MEDICINE (2018)
Driving cars to the clinic for solid tumors
Mauro Castellarin et al.
GENE THERAPY (2018)
Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-decoy strategy
Cristina Basilico et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The multiple paths towards MET receptor addiction in cancer
Leslie Duplaquet et al.
ONCOGENE (2018)
CD44v6 as innovative sarcoma target for CAR-redirected CIK cells
V. Leuci et al.
ONCOIMMUNOLOGY (2018)
Reviving oncogenic addiction to MET bypassed by BRAF (G469A) mutation
Anna Rita Virzi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Receptor Tyrosine Kinase-Targeted Cancer Therapy
Toshimitsu Yamaoka et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Patient-Specific iPSC-Derived Endothelial Cells Provide Long-Term Phenotypic Correction of Hemophilia A
Cristina Olgasi et al.
STEM CELL REPORTS (2018)
Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy
Paolo M. Comoglio et al.
NATURE REVIEWS CANCER (2018)
ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence
Jieyi Wang et al.
CLINICAL CANCER RESEARCH (2017)
Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort
M. Apicella et al.
ONCOGENE (2017)
Disease Modeling in Stem Cell-Derived 3D Organoid Systems
Devanjali Dutta et al.
TRENDS IN MOLECULAR MEDICINE (2017)
Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18
Biliang Hu et al.
CELL REPORTS (2017)
Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
Julia Tchou et al.
CANCER IMMUNOLOGY RESEARCH (2017)
CAR T-cell immunotherapy of MET-expressing malignant mesothelioma
Thivyan Thayaparan et al.
ONCOIMMUNOLOGY (2017)
Regulation of the MET oncogene: molecular mechanisms
Jack Zhang et al.
CARCINOGENESIS (2016)
Improving the safety of T-Cell therapies using an inducible caspase-9 gene
Xiaoou Zhou et al.
EXPERIMENTAL HEMATOLOGY (2016)
MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer
Filippo Pietrantonio et al.
CANCER DISCOVERY (2016)
Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice
Xiaojun Liu et al.
CANCER RESEARCH (2015)
Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity
Hillary G. Caruso et al.
CANCER RESEARCH (2015)
Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes
Ignazio Caruana et al.
NATURE MEDICINE (2015)
High c-Met expression is a negative prognostic marker for colorectal cancer: a meta-analysis
HeLi Gao et al.
TUMOR BIOLOGY (2015)
The Basic Principles of Chimeric Antigen Receptor Design
Michel Sadelain et al.
CANCER DISCOVERY (2013)
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning
Hollie J. Pegram et al.
BLOOD (2012)
The MET Oncogene Is a Functional Marker of a Glioblastoma Stem Cell Subtype
Francesca De Bacco et al.
CANCER RESEARCH (2012)
MET Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib
Jochen K. Lennerz et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Induction of MET by Ionizing Radiation and Its Role in Radioresistance and Invasive Growth of Cancer
Francesca De Bacco et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification
Sai-Hong Ignatius Ou et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Suicide Gene Therapy to Increase the Safety of Chimeric Antigen Receptor-Redirected T Lymphocytes
Monica Casucci et al.
JOURNAL OF CANCER (2011)
MET and KRAS Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase Inhibitors
Virna Cepero et al.
CANCER RESEARCH (2010)
Monovalency Unleashes the Full Therapeutic Potential of the DN-30 Anti-Met Antibody
Giovanni Pacchiana et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
MET signalling: principles and functions in development, organ regeneration and cancer
Livio Trusolino et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Drug development of MET inhibitors: targeting oncogene addiction and expedience
Paolo M. Comoglio et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
MET overexpression turns human primary osteoblasts into osteosarcomas
Salvatore Pantane et al.
CANCER RESEARCH (2006)
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752
GA Smolen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters
M Amendola et al.
NATURE BIOTECHNOLOGY (2005)
T cell activation by antibody-like immunoreceptors: Increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity
M Chmielewski et al.
JOURNAL OF IMMUNOLOGY (2004)
Met, metastasis, motility and more
C Birchmeier et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
S Pennacchietti et al.
CANCER CELL (2003)
Robust and efficient regulation of transgene expression in vivo by improved tetracycline-dependent lentiviral vectors
E Vigna et al.
MOLECULAR THERAPY (2002)
分享论文
